US › Healthcare

Vir Biotechnology Inc (VIR)

US · Healthcare · Biotechnology

$9.17+3.03%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$-29,000

Revenue YoY

-101.0%

Net profit

$-125.7M

Profit YoY

-3.9%

EPS

$-0.85

EPS estimate

$0.48

Net margin

433,431.0%

EPS came in at -0.85 against a street estimate of 0.48 — a miss of 277.1%.

Key statistics

Market cap

$1.46B

Forward P/E

4.3

P/B

1.80

Book value

$5.04

EPS (TTM)

$-3.13

52-week high

$11.66

52-week low

$4.16

50-day MA

$9.31

200-day MA

$8.07

Beta

1.62

Analyst view

Analysts rate Vir Biotechnology Inc a buy (7 buy, 2 hold, 0 sell out of 9) with an average price target of $21.56.

Shareholding

Insiders

6.59%

Institutions

80.83%

Largest institutional holders

Fund	Stake
BlackRock Inc	10.67%
ARCH VENTURE CORP	7.66%
SB INVESTMENT ADVISERS (UK) LTD	6.49%
Vanguard Portfolio Management, LLC	5.46%
GSK PLC	5.07%
State Street Corp	4.23%
Vanguard Capital Management, LLC	3.19%
The Goldman Sachs Group Inc	1.93%

Recent filings & reports

Document	Date
Board / officer change · Q3 2026	2026-07-24
Board / officer change · Q2 2026	2026-06-10
Board / officer change · Q2 2026	2026-05-28
Quarterly report · Q1 2026	2026-05-07
Results announced · Q2 2026	2026-05-06
Proxy statement · Q4 2025	2026-04-16
Annual report FY2025	2026-02-23
Quarterly report · Q3 2025	2025-11-05

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Vir Biotechnology Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.